MacroGenics
MGNX
$4.36
Share price
-14.75%
Change (1 day)
-28.44%
Change (1 year)
Categories
MacroGenics (MGNX) - Total debt
Total debt on the balance sheet as of December 2023 : $33.97 M
According to MacroGenics's latest financial reports the company's total debt is $33.97 M. A company’s total debt is the sum of all current and non-current debts.
MacroGenics - Total debt on balance sheet (from 2018 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $33.97 M | -2.47% |
| 2022-12-31 | $34.83 M | 36.77% |
| 2021-12-31 | $25.46 M | -12.92% |
| 2020-12-31 | $29.24 M | -4.33% |
| 2019-12-31 | $30.57 M | |
| 2018-12-31 | $N/A |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $70.84 B | 208,445.52% | 🇺🇸 USA |
 Eli Lilly LLY | $26.21 B | 77,058.16% | 🇺🇸 USA |
 Amgen AMGN | $64.61 B | 190,100.47% | 🇺🇸 USA |
 Gilead Sciences GILD | $24.98 B | 73,453.91% | 🇺🇸 USA |
 Merck MRK | $35.05 B | 103,090.96% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $57.40 B | 168,894.14% | 🇺🇸 USA |
 Xencor XNCR | $83.43 M | 145.60% | 🇺🇸 USA |